MeiraGTx shares are trading higher after safety and tolerability was confirmed in its gene therapy study for Parkinson's.
Portfolio Pulse from Benzinga Newsdesk
MeiraGTx shares rose following positive results from a gene therapy study for Parkinson's, confirming safety and tolerability.
October 15, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MeiraGTx shares increased after the company announced that its gene therapy study for Parkinson's disease confirmed safety and tolerability.
The confirmation of safety and tolerability in the gene therapy study is a positive development for MeiraGTx, likely boosting investor confidence and driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100